Altmetrics
Downloads
162
Views
80
Comments
0
A peer-reviewed article of this preprint also exists.
Submitted:
18 May 2023
Posted:
18 May 2023
You are already at the latest version
Primer name | Primer sequence |
---|---|
CDH1 FWD (forward) | GGGGTAGTGAGGATCTTGAT |
CDH1 REV (reverse) | TCCTTTTCCACCCCCAAAGA |
CDH2 FWD (forward) | GGCATAGTCTATGGAGAAGT |
CDH2 REV (reverse) | GCTGTTGTCAGAAGTCTCTC |
VIM FWD (forward) | GCTTTCAAGTGCCTTTCTGC |
VIM REV (reverse) | GTTGGTTGGATACTTGCTGG |
ACTB FWD (forward) | CCCAAAGTTCACAATGTGG |
ACTB REV (reverse) | AAGGGACTTCCTGTAACAAC |
# | Symbol |
---|---|
1 | platinum |
2 | Pt2+ |
3 | carboplatin |
4 | dicycloplatin |
5 | enloplatin |
6 | eptaplatin |
7 | iproplatin |
8 | nedaplatin |
9 | oxaliplatin |
10 | picoplatin |
11 | satraplatin |
12 | sebriplatin |
13 | zeniplatin |
14 | platinum agent |
15 | platinum chemotherapy regimen |
16 | platinum-based doublet chemotherapy |
17 | E platinum |
18 | platinum(II) chloride |
19 | platinum agent/trastuzumab |
20 | cisplatin |
21 | platinum chemotherapy regimen/radiotherapy |
22 | platinum-based doublet chemotherapy/taxane |
23 | platinum chemotherapy regimen/vinorelbine |
24 | platinum chemotherapy/taxoid derivative |
25 | platinum-based doublet chemotherapy/vinorelbine |
26 | platinum-based triplet chemotherapy |
27 | adjuvant chemotherapy/platinum agent |
28 | cetuximab/platinum chemotherapy regimen |
29 | gemcitabine/platinum chemotherapy |
30 | paclitaxel/platinum chemotherapy regimen |
31 | platinum-based neoadjuvant chemotherapy |
32 | bevacizumab/platinum chemotherapy/taxoid derivative |
33 | platinum-norsperimidine complex Pt3NSpd2 |
34 | capecitabine/platinum chemotherapy regimen |
35 | bevacizumab/gemcitabine/platinum chemotherapy regimen |
36 | platinum chemotherapy regimen/thoracic radiotherapy |
37 | nonplatinum-based doublet chemotherapy |
38 | platinum acetylacetonate-titanium dioxide nanoparticles |
39 | BP-Cx1-platinum complex BP-C1 |
40 | cetuximab/5-fluorouracil/platinum chemotherapy |
41 | etoposide/platinum chemotherapy regimen |
42 | ormaplatin |
43 | Bamet-UD2 |
44 | NC-4016 |
45 | fluoropyrimidine/platinum-based triplet chemotherapy |
46 | (diaminocyclohexane)(diacetato)(dichloro)platinum |
47 | lobaplatin |
48 | non-pemetrexed containing platinum chemotherapy regimen |
49 | triplatin tetranitrate |
50 | dacplatinum |
51 | cisplatin/etoposide |
52 | cisplatin/docetaxel |
53 | cisplatin/paclitaxel |
54 | carboplatin/paclitaxel |
55 | cisplatin/epirubicin/5-fluorouracil |
Location | Symbol |
---|---|
Cytoplasm | AKT |
CDC42 | |
DOCK10 | |
ERK1/2 | |
FRS2-GRB2-SHP2 | |
GAB1 | |
GRB2 | |
Grb2-Shc1-Sos | |
Ikk | |
JAK | |
Jnk | |
MAP2K4/7 | |
MAP3K1 | |
MAP3K7 | |
MAPK1 | |
MEK | |
MEST | |
MIR155 | |
MIR192 | |
MIR34A | |
MKK3/6 | |
p38MAPK | |
PI3K | |
PTPN11 | |
RAF | |
Ras | |
RHOA | |
SHC1 | |
SMAD2/3 | |
SMURF1 | |
SOS | |
TAB1 | |
VIM | |
Extracellular Space | EGF |
FGF | |
FGF dimer | |
HGF | |
IL6 | |
MMP1 | |
MMP2 | |
MMP9 | |
PDGF | |
Tgfbeta | |
TGFB2 | |
Nucleus | AP1 |
EGR1 | |
ESRP2 | |
ETS1 | |
FOS | |
FOXC2 | |
FOXO1 | |
GSC | |
GSK3B | |
HMGA2 | |
HSF1 | |
ID2 | |
MTOR | |
NFkB | |
SMAD2/3/4 | |
SMAD4 | |
SNAI1 | |
SNAI2 | |
STAT3 | |
TCF3 | |
TWIST1 | |
ZEB1 | |
ZEB2 | |
Plasma Membrane | CDH1 |
CDH2 | |
CLDN3 | |
EGFR | |
ERBB2 | |
FGFR | |
FRS2 | |
IL6R | |
MET | |
OCLN | |
Pdgfr | |
PDGFRA | |
RAC1 | |
TGFBR1 | |
TGFBR2 | |
Tnfreceptor | |
Other | LATS |
MIR200 | |
N-Cadherin | |
PAR6 | |
Tnf | |
YAP/TAZ |
Analysis Name | Comparison contrast | Upregulated log2 cutoff | Project name | Organism |
---|---|---|---|---|
1- ovarian cancer [ovary] cisplatin 1667 | ExperimentGroup => cisplatin 1 day recovery 2 weeks vs monolayer culture | 0.6374 | GSE144232 | human |
1- breast carcinoma [breast] cisplatin 7438 | SamplingTime => 10 to 11 hours after treatment vs NA | 0.344 | GSE28274 | human |
5- malignant pleural mesothelioma [mesothelium] cisplatin;piroxicam 6825 | Treatment:TreatTime[hours] => 8 -> cisplatin;piroxicam vs none | 0.1488 | GSE22445 | human |
1- lung adenocarcinoma (LUAD) [lung] cisplatin 9800 | Treatment => cisplatin vs none | 0.1224 | GSE6410 | human |
1- malignant pleural mesothelioma [mesothelium] cisplatin 6821 | Treatment:TreatTime[hours] => 24 -> cisplatin vs none | 0.1633 | GSE22445 | human |
140- normal control [liver] cisplatin 2334 | TreatTime[days]:Treatment => 1 -> cisplatin vs DMSO | 1.1422 | GSE57805 | rat |
2- breast carcinoma [breast] cisplatin 7439 | SamplingTime => 8 to 9 hours after treatment vs NA | 0.0815 | GSE28274 | human |
2- malignant pleural mesothelioma [mesothelium] cisplatin;piroxicam 6822 | Treatment:TreatTime[hours] => 24 -> cisplatin;piroxicam vs none | 0.539 | GSE22445 | human |
24- normal control [liver] cisplatin 2200 | TreatTime[days]:Treatment => 0.67 -> cisplatin vs DMSO | 1.0049 | GSE57805 | rat |
256- normal control [liver] cisplatin 2324 | Treatment:TreatTime[days] => cisplatin -> 1 vs 0.67 | 0.2943 | GSE57805 | rat |
37- glioblastoma (GBM) [brain] cisplatin 4128 | Treatment => cisplatin vs DMSO | 0.4672 | GSE97460 | human |
4- malignant pleural mesothelioma [mesothelium] cisplatin 6824 | Treatment:TreatTime[hours] => 8 -> cisplatin vs none | 0.1641 | GSE22445 | human |
Symbol | Family |
---|---|
CAS3/SS3 | biologic drug |
miR-1195 (miRNAs w/seed GAGUUCG) | mature microRNA |
mir-124 | microRNA |
mir-338 | microRNA |
mir-379 | microRNA |
mir-434 | microRNA |
mir-515 | microRNA |
mir-622 | microRNA |
MIR124 | group |
MIR499B | microRNA |
ID | Diseases & Functions | Known Regulator-Disease/Function Relationship |
---|---|---|
1 | Cell death of carcinoma cell lines,Cell proliferation of adenocarcinoma cell lines | 11% (2/18) |
2 | Death of embryo,Homologous recombination of DNA | 0% (0/18) |
3 | Cell cycle progression,Cell proliferation of tumor cell lines | 65% (13/20) |
4 | Cell death of breast cancer cell lines,Cell survival | 0% (0/6) |
5 | DNA recombination,Formation of gamma H2AX nuclear focus,Incidence of lymphoma | 0% (0/15) |
6 | Chromosomal aberration,DNA damage,Homologous recombination of DNA,T-cell non-Hodgkin lymphoma | 13% (1/8) |
7 | Formation of gamma H2AX nuclear focus | 13% (1/8) |
8 | Chromosomal aberration,DNA damage,T-cell non-Hodgkin lymphoma | 11% (1/9) |
9 | Death of embryo | 0% (0/5) |
10 | Chromosomal aberration,DNA damage | 13% (1/8) |
microRNAs |
---|
mir-101 |
mir-103 |
miR-125b-2-3p (and other miRNAs w/seed CAAGUCA) |
mir-145 |
mir-22 |
mir-338 |
mir-379 |
mir-515 |
mir-622 |
MIR499B |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated